Use of a chemically modified antisense oligonucleotide library to identify and validate Eg5 (kinesin-like 1) as a target for antineoplastic drug development.
about
Improved targeting of miRNA with antisense oligonucleotidesRecent findings and future directions for interpolar mitotic kinesin inhibitors in cancer therapyNucleophosmin/B23 inhibits Eg5-mediated microtubule depolymerization by inactivating its ATPase activity.Knockdown of TFIIS by RNA silencing inhibits cancer cell proliferation and induces apoptosis.KIF11 inhibition for glioblastoma treatment: reason to hope or a struggle with the brain?Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression.p53 suppresses structural chromosome instability after mitotic arrest in human cells.Quantitative proteomics identify novel miR-155 target proteins.Functional interrogation of breast cancer: from models to drugs.Downregulation of Kinesin spindle protein inhibits proliferation, induces apoptosis and increases chemosensitivity in hepatocellular carcinoma cells.Modular aspects of kinesin force generation machineryUA62784, a novel inhibitor of centromere protein E kinesin-like proteinCellular delivery and photochemical activation of antisense agents through a nucleobase caging strategy.Observation of significant biomarkers in osteosarcoma via integrating module- identification method with attract.Competition for RISC binding predicts in vitro potency of siRNA.Mammary Tumor-Associated RNAs Impact Tumor Cell Proliferation, Invasion, and Migration.Chromosome 20q amplification regulates in vitro response to Kinesin-5 inhibitor.Highly efficient eradication of intracranial glioblastoma using Eg5 siRNA combined with HVJ envelope.The kinesin Eg5 inhibitor K858 induces apoptosis and reverses the malignant invasive phenotype in human glioblastoma cells.Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer.Antiproliferative activity of monastrol in human adenocarcinoma (MCF-7) and non-tumor (HB4a) breast cells.
P2860
Q24547511-ABB195D9-48EF-45A1-8924-C567AE6247A6Q28076992-79A0A46A-9943-4CCB-887B-6464BDC36F69Q30431834-44D19AF3-1817-4AE4-A9C0-48239964D47DQ33333952-F2007999-54E9-4899-B737-569A33AF0B5FQ33471818-F9FE08C2-B8C3-4BE2-81BD-388426E8F02CQ33677872-5560A4CE-6751-4ED5-800E-05CE5B45DDFCQ33766312-8B1326BD-2DE5-4BF8-A8D7-92AE14F84EB1Q33974878-2984E6A0-59DF-4B8F-840F-4CFA28D71C35Q34626308-7B42BBE4-A0EA-4C88-9DA0-3D96338232CEQ35065391-F2D78038-0DE3-44BB-A5D7-2C05684C18E1Q36824558-975658A3-2955-4A89-8E92-B3FB1FB72759Q37081499-5184D18A-14A6-4EFF-9209-19379CC68937Q37376458-BB5642B7-2690-48E9-A0E3-51D1850404D4Q38651373-A4BE12F2-CE3A-4030-8DF3-DF776F2FB85FQ39113952-7540BC38-1546-40D5-9525-123F097B7BF2Q41572775-BB5F014E-8F24-422B-94F4-B1168DCD8277Q41914377-91CB7DF2-7F17-45F0-A274-0442EEDE6AE9Q45887671-601CE282-C93A-4E2A-8B4C-A8527375B308Q47720000-C1D39EFD-098C-4350-BA6C-6472B8866706Q51185142-AE9256B8-698F-4758-9ED6-9208485EC3A4Q51534884-CA34AC54-483D-4187-89FA-F9A54DFD36D4
P2860
Use of a chemically modified antisense oligonucleotide library to identify and validate Eg5 (kinesin-like 1) as a target for antineoplastic drug development.
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Use of a chemically modified a ...... tineoplastic drug development.
@ast
Use of a chemically modified a ...... tineoplastic drug development.
@en
type
label
Use of a chemically modified a ...... tineoplastic drug development.
@ast
Use of a chemically modified a ...... tineoplastic drug development.
@en
prefLabel
Use of a chemically modified a ...... tineoplastic drug development.
@ast
Use of a chemically modified a ...... tineoplastic drug development.
@en
P2093
P1433
P1476
Use of a chemically modified a ...... tineoplastic drug development.
@en
P2093
Cain Murphy
Chenguang Zhao
Erich Koller
Hong Zhang
MingYi Chang
Nicholas M Dean
Peter J Shepard
Robert I Glazer
Scott A Hirsch
Seongjoon Koo
P304
P356
10.1158/0008-5472.CAN-05-1531
P407
P577
2006-02-01T00:00:00Z